Lexaria Bioscience Corp (LEXX)
2.06
-0.10
(-4.63%)
USD |
NASDAQ |
Nov 22, 13:56
Lexaria Bioscience Net Income (Quarterly): -1.782M for May 31, 2024
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| May 31, 2024 | -1.782M |
| February 29, 2024 | -0.6495M |
| November 30, 2023 | -1.179M |
| August 31, 2023 | -1.239M |
| May 31, 2023 | -2.372M |
| February 28, 2023 | -1.298M |
| November 30, 2022 | -1.756M |
| August 31, 2022 | -1.468M |
| May 31, 2022 | -2.383M |
| February 28, 2022 | -1.426M |
| November 30, 2021 | -1.993M |
| August 31, 2021 | -1.178M |
| May 31, 2021 | -2.557M |
| February 28, 2021 | 0.4041M |
| November 30, 2020 | -0.696M |
| August 31, 2020 | -0.8256M |
| May 31, 2020 | -1.361M |
| February 29, 2020 | -0.9503M |
| November 30, 2019 | -0.9073M |
| August 31, 2019 | -1.078M |
| May 31, 2019 | -1.172M |
| February 28, 2019 | -1.148M |
| November 30, 2018 | -0.7014M |
| August 31, 2018 | -1.217M |
| May 31, 2018 | -3.425M |
| Date | Value |
|---|---|
| February 28, 2018 | -1.378M |
| November 30, 2017 | -0.5787M |
| August 31, 2017 | -0.6869M |
| May 31, 2017 | -0.3391M |
| February 28, 2017 | -0.4478M |
| November 30, 2016 | -0.3954M |
| August 31, 2016 | -0.3144M |
| May 31, 2016 | -0.258M |
| February 29, 2016 | -0.2598M |
| November 30, 2015 | -0.3825M |
| August 31, 2015 | -0.5158M |
| May 31, 2015 | -0.4675M |
| February 28, 2015 | -0.4586M |
| November 30, 2014 | -0.3472M |
| July 31, 2014 | -0.568M |
| April 30, 2014 | -0.4933M |
| January 31, 2014 | -0.1019M |
| October 31, 2013 | -0.1263M |
| July 31, 2013 | -0.0577M |
| April 30, 2013 | -0.0475M |
| January 31, 2013 | -0.1121M |
| October 31, 2012 | 0.0314M |
| July 31, 2012 | 0.0681M |
| April 30, 2012 | -0.2321M |
| January 31, 2012 | -0.1189M |
Net Income Definition
Net Income is the total amount of profit earned by a company. This metric boils down to the overall profit that is left from the revenue that a company receives after taking out various operational line items like cost of goods sold, income tax expense, SG&A expense, etc. Eventually, all companies would want to have a consistent positive and growing net income, so that this can be used for various purposes like reinvesting into the company, paying off debt, and potentially paying out dividends to shareholders.
Net Income (Quarterly) Range, Past 5 Years
-2.557M
Minimum
May 2021
0.4041M
Maximum
Feb 2021
-1.348M
Average
-1.298M
Median
Feb 2023
Net Income (Quarterly) Benchmarks
| Aurinia Pharmaceuticals Inc | 14.35M |
| Edesa Biotech Inc | -1.668M |
| Xenon Pharmaceuticals Inc | -62.79M |
| ESSA Pharma Inc | -7.234M |
| ImmunoPrecise Antibodies Ltd | -2.920M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.084M |
| Total Expenses (Quarterly) | 1.827M |
| EPS Diluted (Quarterly) | -0.13 |
| Enterprise Value | 25.27M |
| Profit Margin (Quarterly) | -2.12K% |
| Earnings Yield | -21.36% |
| Normalized Earnings Yield | -20.14 |